SCHEMBL8738719

SCHEMBL8738719

Cc1nc(Cc2ccc(NC(=O)NCCc3ccccc3)cc2)nc(N(C)CC(=O)NC2CCCC2)c1CC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 6/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
EPHX2 P34913 3/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
ALDH1A1 P00352 4/20 0.41
PTGDR2 Q9Y5Y4 2/20 0.40
TBXA2R P21731 1/20 0.40
PTGDR Q13258 1/20 0.40
CNR1 P21554 1/20 0.38
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
AURKB Q96GD4 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1652114 0.92 EPHX1 (0.42) EPHX1NPC1RAB9ASMN1; SMN2EPHX2
SCHEMBL2005214 0.84 PTGDR2 (0.43) EPHX1NPC1RAB9AALDH1A1PTGDR2
SCHEMBL2003191 0.83 TBXA2R (0.43) EPHX1NPC1RAB9ASMN1; SMN2EPHX2
SCHEMBL1652069 0.82 PTGDR2 (0.44) EPHX1RAB9ASMN1; SMN2EPHX2TP53
SCHEMBL1652427 0.79 TBXA2R (0.40) EPHX1NPC1RAB9AEPHX2ALDH1A1
SCHEMBL2007358 0.79 PTGDR2 (0.51) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL8738226 0.78 PTGDR2 (0.44) NPC1RAB9ASMN1; SMN2EPHX2ALDH1A1
SCHEMBL8738079 0.78 PTGDR2 (0.40) EPHX1EPHX2ALDH1A1PTGDR2TBXA2R
SCHEMBL8737667 0.77 ALDH1A1 (0.48) NPC1SMN1; SMN2EPHX2ALDH1A1PTGDR2
SCHEMBL1652083 0.77 KMT2A (0.43) EPHX1NPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129820-A1 NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129820-A1 NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS HRH2, HRH1, HRH4 EPHX1 523/4885NPC1 1167/4885RAB9A 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.